Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from Vera Therapeutics ( (VERA) ) is now available.
Vera Therapeutics announced an updated corporate presentation at the J.P. Morgan Healthcare Conference, highlighting the progress of their lead therapy, atacicept, in clinical trials. The company is positioned strongly with $677 million in cash and marketable securities, and is focused on potential commercial launch plans, bolstered by breakthrough therapy designation from the FDA for atacicept in treating IgAN. The company aims to expand atacicept’s indications to other autoimmune and kidney diseases, with several clinical trials underway.
More about Vera Therapeutics
Vera Therapeutics is a biopharmaceutical company focused on developing transformative therapies for patients with serious immunological diseases. Its primary product is atacicept, a dual BAFF/APRIL B cell modulator, which is being developed as a potential treatment for IgA nephropathy (IgAN) and other autoimmune diseases.
YTD Price Performance: -12.27%
Average Trading Volume: 745,286
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $2.34B
Find detailed analytics on VERA stock on TipRanks’ Stock Analysis page.
